Literature DB >> 6363078

Efficacy, duration and mechanism of action of nifedipine in stable exercise-induced angina pectoris.

D Ardissino, S De Servi, J A Salerno, G Specchia, M Previtali, A Mussini, P Bobba.   

Abstract

The duration of effect of single oral doses of 10 and 20 mg of nifedipine was studied in 10 patients with angiographically proven coronary artery disease and with stable exercise-induced angina pectoris. In a randomized double-blind manner exercise tests were carried out 1 hour before and 1, 2, 4 and 6 h after the administration of placebo, nifedipine 10 mg(N10) and nifedipine 20 mg(N20). Compared with the placebo both N10 and N20 produced a statistically significant increase in exercise tolerance at 1(P less than 0.05), 2(P less than 0.01), 4(P less than 0.01) and 6(P less than 0.05) hours after N10 and at 1(P less than 0.01), 2(P less than 0.01), 4(P less than 0.01) and 6(P less than 0.05) hours after N20. At peak exercise the product of heart rate X systolic blood pressure (RPP) was significantly increased compared with placebo at 2, 4 and 6 h after N10 and at 2, 4 and 6 h after N20 with maximal ST-segment depression unchanged. At the same duration of exercise at which angina had occurred during control studies the RPP was unaffected by nifedipine while a statistically significant reduction of ST-segment depression was seen at 1, 2 and 4 h after N10 and at 1, 2 and 4 h after N20. Direct measurements of great cardiac vein flow during exercise in two patients showed that nifedipine is effective in preventing the abnormal increase of exercise-induced coronary tone in the area supplied by stenotic vessels.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6363078     DOI: 10.1093/oxfordjournals.eurheartj.a061415

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  8 in total

Review 1.  Increased coronary tone in exertional angina: the beneficial effects of calcium antagonists.

Authors:  G Specchia; D Ardissino; S Ghio; P Barberis; M L Colombo; S De Servi
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  Acute effects of nifedipine versus isosorbide dinitrate on exercise tolerance in patients with isolated coronary artery occlusion and collaterals.

Authors:  F Barillà; F Pelliccia; A Valente; C Cianfrocca; F Romeo; A Reale
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 3.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 4.  Pharmacology of acute effort angina.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

5.  Slow release nifedipine plus atenolol in chronic stable angina pectoris.

Authors:  V F Challenor; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

6.  Evaluation of the antianginal effect of nifedipine: influence of formulation dependent pharmacokinetics.

Authors:  B W Karlson; H Emanuelsson; J Herlitz; J E Nilsson; G Olsson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 7.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

8.  24-hour anti-ischaemic action with once daily nifedipine. Experience obtained with a fatty-alcohol matrix tablet in patients with coronary artery disease.

Authors:  B G Woodcock; P A Thürmann; S Pfleiderer; N Reifart
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.